Cytotoxic Activity and In Silico Study of Secondary Metabolites Derived from Dactylospongia elegans
Marine Drugs · 04.08.2026 · 24 (8) · 271
DOI: 10.3390/md24080271 ↗Kurz gefasst
Fachartikel in der Zeitschrift Marine Drugs, online erschienen am 04.08.2026. Verfasst von Yuni Elsa Hadisaputri und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Biology, Faculty of Pharmacy, Universitas Padjadjaran, Jatinangor 45363, Indonesia. Hauptthemen laut MEDLINE: Porifera, Antineoplastic Agents. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Indonesia Endowment Fund for Education, Universitas Padjadjaran.
Abstract (Originalsprache)
Breast cancer remains a major global health burden. Dactylospongia species have been explored for their cytotoxic potential. This study aims to evaluate the cytotoxic potential of compounds derived from the marine sponge Dactylospongia elegans. Dactylospongia elegans were collected from the Lembeh Strait, macerated using methanol, then partitioned to an ethyl acetate fraction. The cytotoxic activity of these fractions was assessed using MDA-MB-231 cells while toxicity testing was done using the BSLT. TLC was carried out to determine the groups of compounds, while LC-MS/MS was used to predict active compounds contained in the ethyl acetate fractions. In silico studies were conducted as preliminary studies to determine the antitumor mechanism. The ethyl acetate fraction and F4 subfraction of Dactylospongia elegans exhibited cytotoxicity toward MDA-MB-231 cells with IC50 values of 15.72 and 41.76 µg/mL, respectively. The BSLT indicated the strongest toxicity belongs to the F6 subfraction (LC50 = 32.831 µg/mL). TLC analysis confirmed the presence of major secondary metabolites as terpenoids, steroids, and alkaloids, then confirmed with LC-MS/MS including 5-epi-illimaquinone and calciferol. Molecular docking revealed that calciferol exhibited the strongest binding affinity toward tyrosine kinase and p53–MDM2 receptors, with binding energies of −10.13 and −10.28 kcal/mol, respectively. These findings suggest that Dactylospongia elegans contains bioactive constituents with potential anticancer activity, particularly against TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Biology, Faculty of Pharmacy, Universitas Padjadjaran, Jatinangor 45363, Indonesia.
- Graduate School, Universitas Padjadjaran, Bandung 40132, Indonesia.
- Research Center for Vaccine and Drugs, Research Organization for Health, National Research and Innovation Agency (BRIN), Bogor 16911, Indonesia.
- Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran, Jatinangor 45363, Indonesia.
- Laboratory of Pharmacology and Toxicology, Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta 55281, Indonesia.
- Department of Bioscience and Biotechnology, Faculty of Agriculture, University of the Ryukyus, Nishihara 903-0213, Japan.
ORCID-Profile: Yuni Elsa Hadisaputri, Tutik Murniasih, Ariyono Hadi, Mutakin Mutakin, Elin Julianti
Förderung
- Indonesia Endowment Fund for Education
- Universitas Padjadjaran
Zitieren
APA
Hadisaputri, Y. E., Hidayat, N. N., Murniasih, T., Hadi, A., Mutakin, M., Yuniati, N., Asikin, Y., & Julianti, E. (2026). Cytotoxic Activity and In Silico Study of Secondary Metabolites Derived from Dactylospongia elegans. Marine Drugs, 24(8), 271. https://doi.org/10.3390/md24080271
Vancouver
Hadisaputri YE, Hidayat NN, Murniasih T, Hadi A, Mutakin M, Yuniati N, et al. Cytotoxic Activity and In Silico Study of Secondary Metabolites Derived from Dactylospongia elegans. Marine Drugs. 2026;24(8):271. doi:10.3390/md24080271
BibTeX
@article{Hadisaputri2026,
author = {Hadisaputri, Yuni Elsa and Hidayat, Nafisa Nurfatia and Murniasih, Tutik and Hadi, Ariyono and Mutakin, Mutakin and Yuniati, Nunung and Asikin, Yonathan and Julianti, Elin},
title = {Cytotoxic Activity and In Silico Study of Secondary Metabolites Derived from Dactylospongia elegans},
journal = {Marine Drugs},
year = {2026},
volume = {24},
number = {8},
pages = {271},
doi = {10.3390/md24080271}
}
EUVIMED